Incyte weekly recap highlights MPNs Phase III/POC data

Incyte reported positive proof-of-concept and Phase III data across MPNs, solid tumors and dermatology, closed the Vega Therapeutics deal adding latarcibart, and outlined plans to grow post-2029 while expecting JAKAFI XR formulary uptake and potential further milestones for zilurgisertib.